Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

taurolidine-heparin

taurolidine-heparin
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Defencath SOLUTION, INTRAVENOUS 13.5 mg / mL, 1,000 USP Units / mL      
Comments:

Restricted to use in High Value Care Committee approved unattached dialysis patients by Infectious Disease and Nephrology prior to discharge.

As of October 2025, one patient (OBC) is eligible.

 

 

Reviewed: September 2025  

Taurolidine and Heparin (DEFENCATH) Spotlight.pdf

Taurolidine and Heparin (DEFENCATH) Spotlight_HVCC Updated October 2025.pdf

Last updated: Nov. 14, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved